Who: Luca Salassa. CIC BiomaGUNE
Place: Donostia International Physics Center (DIPC). Paseo Manuel de Lardizabal, 4, Donostia
Date: Friday, 6 November 2015, 12:00
Fostered by the success of photodynamic therapy (PDT), the use of light to activate prodrugs
is currently gaining momentum in biomedical research. In principle, photoactivation allows to
spatially and temporally control the biological effects of a prodrug, hence conferring selectivity
to its action and reducing unwanted drawbacks.
In the last few years, photoactivatable transition metal complexes have been studied
intensively for application in chemotherapy . The interest in this class of derivatives is
motivated by a rich photochemistry which can be tailored to promote novel mechanisms of
action. Nevertheless, the poor absorption properties of metal complexes in the therapeutic
windows of the visible spectrum ( ? > 600 nm) pose a key limitation for further advancing their
use towards preclinical and clinical PDT.
Upconversion nanoparticles (UCNPs) and their outstanding optical properties offer a superior
and effective strategy to achieve efficient photoactivation of metal complexes and overcome
their intrinsic flaws [2,3]. Notably, UCNPs can be exploited to access excitedstate
chemistryin metal complexes using near infrared light and design innovative hybrid materials for
imaging and therapy. In this contribution we will discuss our advances in this emerging field.
Financial support by the Spanish Ministry of Economy and Competitiveness (grant CTQ2012-
39315 and Ramón y Cajal Fellowship RYC201107787), the EU PF7 program (MCCIG
fellowship PCIG11GA2012321791) and the Department of Industry of the Basque Country
(grant ETORTEK) is acknowledged.
1. Schatzschneider, U.; Eur. J. Inorg. Chem. 2010, 10, 14511467.
2. Ruggiero, E.; Habtemariam, A.; Yate, L.; MarequeRivas,
J. C.; Salassa, L.; Chem.
Commun., 2014, 50, 17151718.
3. Ruggiero, E.; HernándezGil,